Breaking News Instant updates and real-time market news.

PFE

Pfizer

$37.33

-0.03 (-0.08%)

16:26
07/20/18
07/20
16:26
07/20/18
16:26

FDA approves Pfizer's Biosimilar NIVESTYM for all indications

Pfizer announced that the United States Food and Drug Administration has approved NIVESTYM, a biosimilar to Neupogen, for all eligible indications of the reference product. The FDA approval was based on a review of a comprehensive data package and totality of evidence demonstrating a high degree of similarity of NIVESTYM compared to its reference product. NIVESTYM is expected to be available in the U.S. at a significant discount to the current wholesale acquisition cost of Neupogen. WAC is not inclusive of discounts to payers, providers, distributors and other purchasing organizations.

  • 22

    Aug

  • 10

    Sep

PFE Pfizer
$37.33

-0.03 (-0.08%)

07/17/18
HCWC
07/17/18
NO CHANGE
Target $42
HCWC
Buy
uniQure pullback on Pfizer study unwarranted, says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay notes that shares of uniQure (QURE) dropped 11% yesterday after Pfizer (PFE) initiated an "open-label, non-investigational product, multi-center, lead-in study to evaluate at least 6 months of prospective efficacy and selected safety data of factor IX prophylaxis replacement therapy in moderate to severe adult Hemophilia B subjects who are negative for neutralizing antibodies to adeno-associated virus vector-spark100". This has been potentially misconstrued as the initiation of the Phase 3 study, suggesting competitive threats for uniQure earlier than anticipated, Chattopadhyay tells investors in a research note. However, this is not to be mistaken as a gene therapy Phase 3 program, as there is no gene therapy treatment cohort, the analyst adds. Further, Chattopadhyay points out that Pfizer's observation study is expected to be completed during November of 2020, which he believes puts uniQure at least a year, if not more, ahead. In addition, the analyst continues to believe that Pfizer is likely to encounter intellectual property headwinds given uniQure's patent asset protecting both the mPadua gene cassette and its method of use to treat hemoglobinopathies. He views the selloff yesterday in shares of uniQure as unwarranted and keeps a Buy rating on the name with a $42 price target.
07/17/18
CANT
07/17/18
NO CHANGE
CANT
Overweight
Aclaris offers best risk/reward of hair loss players, says Cantor Fitzgerald
The potential for JAK inhibitors to treat alopecia areata may be underappreciated by investors because the Street does not appear to be ascribing enough value to the opportunity, Cantor Fitzgerald analyst Louise Chen tells investors in a research note. Of the three companies she covers developing JAKs for hair loss, Aclaris Therapeutics (ACRS), Eli Lilly (LLY) and Pfizer (PFE), the analyst believes Aclaris offers the best risk/reward and greatest upside potential. The company has a market cap below $700M and two potential "shots on goal" for alopecia areata, Chen writes. She estimates combined peak sales of $1B-plus for both opportunities and keeps an Overweight rating on Aclaris. The physicians the analyst spoke to believe the company's JAKs for hair loss will work.
07/18/18
PIPR
07/18/18
NO CHANGE
Target $450
PIPR
Overweight
Piper maintains Overweight on Regeneron on tanezumab news
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Regeneron Pharmaceuticals (REGN) on news that tanezumab, Pfizer (PFE) and Eli Lilly's (LLY) anti-NGF antibody that is a competitor to Regeneron's fasinumab, successfully completed the first of several Phase 3 trials. Fasinumab remains an unmodeled opportunity, but the read-through from tanezumab is positive and the market for an effective, non-opioid chronic pain treatment is "massive," Raymond tells investors in a research note. The analyst points out that Regeneron and Teva (TEVA) still expect to report Phase 3 data starting later this year. Raymond keeps an Overweight rating on Regeneron with a $450 price target.
07/18/18
WELS
07/18/18
NO CHANGE
WELS
Novartis report has negative read through for Teva, Mylan, says Wells Fargo
Wells Fargo analyst David Maris noted that Novartis (NVS) lowered its 2018 guidance for Sandoz along with its Q2 report and reportedly told Bloomberg that it would consider selling the generic drug unit. He sees a negative read through for companies with large U.S. commodity generic exposure, such as Teva (TEVA) and Mylan (MYL), from Novartis' report, Maris tells investors. He also noted that Novartis said it will not increase prices on its drugs in the U.S. for the rest of 2018, as Pfizer (PFE) recently has also said, calling this "a wise approach and correct read of the increasing intensity of the scrutiny around rising healthcare costs." Maris continues to expect the " chilling effect" on price increases to spread through the industry. Lastly, the analyst pointed out that the Amgen-partnered (AMGN) launch of Aimovig is off to a strong start, which he believes bodes well for Teva's fremanezumab and Eli Lilly's (LLY) galcanezumab.

TODAY'S FREE FLY STORIES

03:30
08/15/18
08/15
03:30
08/15/18
03:30
General news
FX Action: USD-CAD found support at yesterday's three-session low »

FX Action: USD-CAD found…

02:20
08/15/18
08/15
02:20
08/15/18
02:20
General news
FX Update: The Dollar has posted broad gains »

FX Update: The Dollar has…

01:55
08/15/18
08/15
01:55
08/15/18
01:55
General news
Asian Market Wrap: »

Asian Market Wrap:…

SPWR

SunPower

$6.89

-0.09 (-1.29%)

, SUNEQ

SunEdison

$0.00

(0.00%)

21:08
08/14/18
08/14
21:08
08/14/18
21:08
Periodicals
China lodges WTO complaint about U.S. solar tariffs, Reuters says »

China Commerce Ministry…

SPWR

SunPower

$6.89

-0.09 (-1.29%)

SUNEQ

SunEdison

$0.00

(0.00%)

CSIQ

Canadian Solar

$13.33

-0.27 (-1.99%)

JASO

JA Solar

$0.00

(0.00%)

TSL

Trina Solar

$0.00

(0.00%)

FSLR

First Solar

$52.01

-0.48 (-0.91%)

SCTY

Bought by TSLA

$0.00

(0.00%)

YGE

Yingli Green Energy

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

GS

Goldman Sachs

$229.53

2.7 (1.19%)

20:39
08/14/18
08/14
20:39
08/14/18
20:39
Periodicals
Judge allows Goldman shareholders to pursue 2008 CDO class action, Reuters says »

U.S. District Court judge…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$41.87

1.79 (4.47%)

, PFGC

Performance Food Group

$37.60

0.7 (1.90%)

20:25
08/14/18
08/14
20:25
08/14/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

M

Macy's

$41.87

1.79 (4.47%)

PFGC

Performance Food Group

$37.60

0.7 (1.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 15

    Aug

  • 17

    Sep

FAF

First American

$56.46

0.04 (0.07%)

20:16
08/14/18
08/14
20:16
08/14/18
20:16
Hot Stocks
First American raises quarterly dividend by 11% to 42c per share »

The cash dividend is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

BAS

Basic Energy

$8.61

-0.11 (-1.26%)

20:12
08/14/18
08/14
20:12
08/14/18
20:12
Hot Stocks
Basic Energy names David Schorlemer as new CFO »

Basic Energy Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

MRT

MedEquities Realty Trust

$10.00

0.16 (1.63%)

19:45
08/14/18
08/14
19:45
08/14/18
19:45
Periodicals
MedEquities Realty Trust exploring a sale, Bloomberg reports »

MedEquities Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$9.50

0.04 (0.42%)

19:26
08/14/18
08/14
19:26
08/14/18
19:26
Periodicals
Ford plans to invest $740M to revamp Detroit station, other sites, Reuters says »

Ford said it plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 31

    Aug

PETQ

PetIQ

$28.26

1 (3.67%)

, PRSP

Perspecta

$21.64

-0.31 (-1.41%)

19:00
08/14/18
08/14
19:00
08/14/18
19:00
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: PetIQ…

PETQ

PetIQ

$28.26

1 (3.67%)

PRSP

Perspecta

$21.64

-0.31 (-1.41%)

FENG

Phoenix New Media

$4.12

-0.055 (-1.32%)

EGN

Energen

$73.15

1.76 (2.47%)

FANG

Diamondback Energy

$133.75

1.84 (1.39%)

ADNT

Adient

$42.65

0.19 (0.45%)

ERI

Eldorado Resorts

$43.85

0.55 (1.27%)

TEVA

Teva

$22.12

0.17 (0.77%)

CASA

Casa Systems

$15.62

-0.17 (-1.08%)

A

Agilent

$66.72

0.77 (1.17%)

CREE

Cree

$50.17

-0.11 (-0.22%)

VRAY

ViewRay

$9.89

-0.01 (-0.10%)

CRZO

Carrizo Oil & Gas

$24.31

0.62 (2.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 19

    Aug

  • 21

    Aug

  • 28

    Aug

  • 04

    Sep

  • 10

    Sep

  • 16

    Sep

  • 15

    Aug

  • 15

    Aug

AAP

Advance Auto Parts

$156.01

11.22 (7.75%)

18:47
08/14/18
08/14
18:47
08/14/18
18:47
Upgrade
Advance Auto Parts rating change at Citi »

Advance Auto Parts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

SPHS

Sophiris Bio

$2.74

0.13 (4.98%)

18:37
08/14/18
08/14
18:37
08/14/18
18:37
Recommendations
Sophiris Bio analyst commentary at Piper Jaffray »

Sophiris Bio topsalycin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$52.87

0.65 (1.24%)

, GOOG

Alphabet

$1,241.95

6.85 (0.55%)

18:30
08/14/18
08/14
18:30
08/14/18
18:30
Hot Stocks
Verizon to partner with YouTube TV for 5G residential broadband package »

Verizon (VZ) announced it…

VZ

Verizon

$52.87

0.65 (1.24%)

GOOG

Alphabet

$1,241.95

6.85 (0.55%)

GOOGL

Alphabet Class A

$1,258.15

9.39 (0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 14

    Aug

  • 22

    Aug

  • 18

    Sep

  • 20

    Sep

  • 28

    Oct

NVDA

Nvidia

$261.47

5.39 (2.10%)

18:27
08/14/18
08/14
18:27
08/14/18
18:27
Upgrade
Nvidia rating change at Wells Fargo »

Nvidia double-upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

ORCL

Oracle

$48.23

0.21 (0.44%)

, RMNI

Rimini Street

$6.01

0.11 (1.86%)

18:26
08/14/18
08/14
18:26
08/14/18
18:26
Hot Stocks
Court grants Oracle's motion for permanent injunction against Rimini Street »

For the second time, a…

ORCL

Oracle

$48.23

0.21 (0.44%)

RMNI

Rimini Street

$6.01

0.11 (1.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$261.47

5.39 (2.10%)

18:22
08/14/18
08/14
18:22
08/14/18
18:22
Upgrade
Nvidia rating change at Wells Fargo »

Nvidia double-upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

CVS

CVS Health

$71.39

1.88 (2.70%)

18:20
08/14/18
08/14
18:20
08/14/18
18:20
Hot Stocks
CVS Health says 'actively working' with Ohio Managed Medicaid clients »

"CVS Health is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

VRAY

ViewRay

$9.89

-0.01 (-0.10%)

18:18
08/14/18
08/14
18:18
08/14/18
18:18
Syndicate
ViewRay $125M Spot Secondary; price range $9.25-$9.50 »

Morgan Stanley, Jefferies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 04

    Sep

CRZO

Carrizo Oil & Gas

$24.31

0.62 (2.62%)

18:16
08/14/18
08/14
18:16
08/14/18
18:16
Syndicate
Carrizo Oil & Gas 9.5M share Spot Secondary; price range $22.90-$23.50 »

Citi and Goldman Sachs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 15

    Aug

WTW

Weight Watchers

$77.39

1.8 (2.38%)

18:12
08/14/18
08/14
18:12
08/14/18
18:12
Syndicate
Weight Watchers 6M share Block Trade; price range $76.00-$77.00 »

Morgan Stanley is acting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERI

Eldorado Resorts

$43.85

0.55 (1.27%)

, PAY

Verifone

$23.00

-0.02 (-0.09%)

18:05
08/14/18
08/14
18:05
08/14/18
18:05
Hot Stocks
S&P announces changes to S&P MidCap 400 index »

S&P Dow Jones Indices…

ERI

Eldorado Resorts

$43.85

0.55 (1.27%)

PAY

Verifone

$23.00

-0.02 (-0.09%)

ADNT

Adient

$42.65

0.19 (0.45%)

DCT

DCT Industrial

$65.28

-0.34 (-0.52%)

PLD

Prologis

$64.05

-0.38 (-0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$116.73

0.7 (0.60%)

18:00
08/14/18
08/14
18:00
08/14/18
18:00
Hot Stocks
Celanese to increase price of acetate flake by 50c/kg »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

GDDY

GoDaddy

$75.81

0.52 (0.69%)

17:43
08/14/18
08/14
17:43
08/14/18
17:43
Syndicate
GoDaddy files to sell 10,398,942 shares of Class A common stock »

Selling stockholders are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAG

MAG Silver

$8.64

0.07 (0.82%)

17:41
08/14/18
08/14
17:41
08/14/18
17:41
Earnings
MAG Silver reports Q2 EPS (3c), consensus (2c) »

Reports cash and cash…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.